Abstract
Advances in next-generation sequencing have provided new insights and new therapeutic options for patients with cancer. However, assessment of genomic aberrations, which is required for precision medicine, has been challenging because of the difficulties in capturing intratumoral heterogeneity and in real-time assessment of tumors. Recent advances in technology have enabled detection and analysis of cell-free DNA in cancer patients, which provides real-time assessment of tumor evolution. Here, we review the recent advances in our understanding of the clinical utility of cell-free DNA and the future directions for its use in cancer management.
Funding Information
  • Elsa U Pardee Foundation, the Sidney Kimmel Foundation for Cancer Research
  • the Sheikh Khalifa Al Nahyan Ben Zayed Institute
  • the National Center for Advancing Translational Sciences (UL1 TR000371)
  • National Institutes of Health through MD Anderson’s Cancer Center ((P30 CA016672))
  • Novartis, BioMed Valley Discoveries, Astellas,
  • Foundation Medicine, Biocartis, Trovagene and Transgenomic

This publication has 56 references indexed in Scilit: